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Identity 
Other names: erg-3; p55 
HGNC (Hugo): ERG 
Location: 21q22.2 
 






The ERG gene belongs to the erythroblast 
transformation-specific (ETS) family of transcriptions 
factors. The ERG gene (ETS related gene 1) is located 
on chromosome 21, and consists of 17 exons, 
approximately 300 kb DNA in length. 
Transcription 
The ERG gene forms 20 known transcripts (ranging 
from 560 to 5034 bp in length), amongst which 15 are 
coding for proteins, and 5 are non-coding. 8 alternative 
splice variants are known. 
Pseudogene 
No observed pseudogenes. 
 
ERG gene locus on the q-arm of chromosome 21 (21q22.2) spanning from 39751949 to 40033704 (according to UCSC genome browser, 
Feb. 2009 GRCh37/hg19, and Ensemble, Aug. 2010). 
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Protein 
Description 
Amongst the 20 known transcripts of the ERG gene, 15 
are protein coding. The 15 proteins range from 171 to 
486 amino acids in length, and up to 55 kDa in weight. 
Expression 
On the protein level, ERG is mainly expressed in the 
nucleus and is rarely seen in the cytoplasm. Basically, 
in the GNF SymAtlas database, major ERG expression 
was found to be in CD34+ cells (that include both 
hematopoietic stem cells and endothelial cells). In 
detail, ERG is reported to be expressed during early T 
and B cell development, and down-regulated in later 
stages of B and T cell differentiation. Also, ERG is 
expressed in platelets, megakaryoblastic cell lines, 
primary megakaryoblastic leukemia (AMKL or M7-
AML) in Down syndrome patients. Furthermore, ERG 
is strongly expressed in ERG gene rearranged prostate 
tissue (both in prostatic cancer tissue and adjacent 
prostatic intraepithelial neoplasia lesions). Of note, 
using immunohistochemistry, ERG expression is 
regularly observed in lymphocytes and small blood 
vessels. 
Localisation 
Predominantely nuclear and rarely cytoplasmic. 
Function 
The ERG protein is a member of the ETS-family and is 
known to bind to purine-rich sequences. ERG and other 
members of the same family are downstream regulators 
of mitogenic signal transduction pathways. They are
key regulators of embryonic development, cell 
proliferation, differentiation, angiogenesis, 
inflammation, and apoptosis. At the DNA level, 
isoforms of ERG are known to regulate methylation. 
Further, ERG is required for platelet adhesion to the
subendothelium, inducing vascular cell remodeling. 
Moreover, hematopoesis, as well as the differentiation 
and maturation of megakaryocytic cells are regulated 
by ERG. Overexpression of the ERG protein is 
suggested to aid in forming solid tumors. However, the 
exact molecular mechanisms of ERG as a transcription 
factor are still unknown. 
Homology 
A member of the ETS transcription factors, most 
homologous to FLI1. 
Mutations 
Note 







The prognostic relevance of an ERG gene fusion or an 
ERG overexpression in Ewing's sarcoma (EWS-ETS 
fusion type) is yet to be determined. So far, no 
prognostic relevance could be shown. 
Hybrid/Mutated gene 
If a gene fusion occurs in Ewing's sarcoma, most 
frequently it is a fusion of EWS to FLI-1 (in app. 85% 
of cases) or ERG (in app. 10% of cases). Other ETS 
genes rarely serve as EWS gene fusion partners (in app. 
5% of cases). 
Abnormal protein 
The EWS gene fuses with the carboxyl terminal of 
ERG containing the ETS DNA binding domain of 
ERG. Therefore, the resulting fusion protein 
deregulates a large number of genes by so far poorly 
defined mechanisms. 
Oncogenesis 
In a transgenic mouse model expression of the EWS-
ERG in lymphoid progenitors induced T-cell leukemia. 
Acute myeloid leukemia (AML) 
Prognosis 
Several studies suggest a poorer prognosis for FUS-
ERG gene fusion positive AML as compared to non-
fused AML. Moreover, an ERG overexpression, not 
necessarily due to the FUS-ERG gene fusion, predicts 
an increased relapse risk and shorter survival in AML 
patients. However, the exact contribution of ERG 
overexpression to myeloid leukemiogenesis and 
progression is still unknown. 
Hybrid/Mutated gene 
In the FUS-ERG gene fusion, the FUS gene fuses with 
the carboxyl terminal of ERG containing the ETS DNA 
binding domain of ERG. Of note, in a single case, a 
gene fusion of ERG with the myeloid ELF-like factor 1 
(ELF4) was detected. 
Oncogenesis 
The FUS-ERG fusion protein helps in activating the 
oncogenic activity of transcription factors. 
Prostate cancer 
Prognosis 
The body of literature is controversial about the 
prognostic relevance of ERG rearrangements in 
prostate cancer. Some studies reported an association of 
the ERG rearrangement with adverse clinical 
parameters (i.e. time to prostate cancer specific death 
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Schematic displaying ERG rearrangement status (via FISH) in prostate cancer. The red-labelled centromeric and the green-labelled 
telomeric probes span the ERG locus on chromosomes 21. If a break-apart occurs, the green signal is either lost (ERG rearrangement 
through deletion) or translocated (ERG rearrangement through insertion). An ERG break-apart as determined by FISH accounts for a 
fusion of ERG mainly with TMPRSS2 but also with other 5' fusion partners such as SLC45A3, HERPUD1, or NDRG1. A: Both alleles with 
wild type (wt) ERG. B: One allele with ERG rearrangement through deletion (single red signal) and the other allele with wt ERG (yellow 
signal). C: One allele with ERG rearrangement through insertion (separated red and green signal) and the other allele with wt ERG 
(yellow signal). 
 
On the other hand, some studies demonstrated an 
association of ERG rearrangement with parameters of 
more favourable outcome, such as lower Gleason score, 
stage, volume, better overall survival, or late 
biochemical recurrence. Interestingly, a subset of 
studies without any such association was reported as 
well. 
Hybrid/Mutated gene 
In approximately 50% of prostate cancers, the ERG 
gene is rearranged, i.e. fused to another gene. In case of 
a rearrangement, TMPRSS2 is the ERG 5' fusion 
partner in the vast majority of cases (app. 85%). Other 
known, but rarely occurring ERG fusion partners 
include NDRG1, SLC45A3, and HERPUD1. The ERG 
gene rearrangement either occurs due to a deletion, or 
an insertion. 
Abnormal protein 
An ERG gene rearrangement in prostate cancer mainly 
results in an androgen dependant ERG overexpression. 
Oncogenesis 
In-vitro models complement that over expression of 
truncated ERG and various TMPRSS2-ERG isoforms 
increase cell migration and invasion. In-vivo 
recapitulation of ETS fusions by prostate specific 
expression of truncated ERG in mice resulted in the 
development of PIN but not carcinoma. Subsequent  
work on transgenic TMPRSS2-ERG mice develop PIN 
progressing to invasive cancer, but only in the context 
of PI3-kinase pathway activation. TMPRSS2-ERG-
positive human tumors are also enriched for PTEN 
loss, suggesting cooperation in prostate tumorigenesis. 
Acute lymphoblastic leukemia (ALL) 
Prognosis 
Overexpression of ERG was shown to be a risk factor 
in adult T-ALL. ALL patients with ERG 
overexpression were four times more likely to fail long-
term recurrence free survival, indicating inferior 
survival. 
Oncogenesis 
Studies assessing ERG overexpression in ALL have 
shown that due to the involvement of ERG in T-cell 
development, it may have an oncogenic potential. 
Acute megakaryoblastic leukemia 
(AMKL) 
Prognosis 
Even though ERG is highly considered to be oncogenic 
in AMKL, no prognostic relevance has been 
determined. 
Oncogenesis 
ERG was found to be expressed megakaryoblastic 
leukemic cell lines and in primary leukemic cells from  
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DS patients. Moreover, in mouse models, expression of 
ERG drove megakaryopoiesis and lead to a rapid 
development of aggressive leukemia. 
Alzheimer's disease (AD) 
Note 
ERG has been linked to AD, due to an ERG protein 
overexpression as compared to control patients. This is 
further supported by experiments conducted on patients 
suffering from Down syndrome, who gradually develop 
AD-like symptoms, linked to ERG overexpression. 
Down syndrome (DS) 
Note 
DS is associated with trisomy of the chromosome 21, 
where the ERG gene is located. The trisomy is 
considered to be responsible for an ERG 
overexpression. In a DS mouse model, an induced 
functional disomy of the ERG allele corrects some 
pathologic features of the disease, including 
myeloproliferation and progenitor cell expansion, 




ERG involvement in endothelial 
development 
Note 
ERG has been reported to regulate genes involved in 
chondrogenesis and angiogenesis and functions as a 
modulator of endothelial cell differentiation. In a in-
vitro study, the decrease of the ERG protein follows a 
reduction in endothelial cell proliferation and vascular 
tube formation. In human umbilical vein endothelial 
cell lines, vascular endothelial growth factor (VEGF) 
was seen to significantly up-regulate ERG expression. 
Controversially, on the other hand, ERG expression 
was shown to inhibit responsiveness to the VEGF 
receptor in a Down Syndrome mouse model. 
ERG involvement in lymphoid 
development 
Note 
ERG was reported to be expressed in during early T 
and B cell development, and to be down-regulated in 
later stages of B and T cell differentiation. In detail, the 
ERG protein modulates the maturation of lymphoid 
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